New Board members and new Chairman of the Board are proposed in Karessa Pharma Holding AB (publ)
Ulf Lindberg is proposed as new Chairman of the Board and incoming CEO, Michael Brobjer, is proposed as new Board member of Karessa Pharma Holding AB (publ).
The Board proposes to elect Ulf Lindberg and Michael Brobjer as new Board members and that Ulf Lindberg will be elected as new Chairman of the Board at the Extraordinary General Meeting on March 3rd 2017.
Ulf Lindberg
Ulf Lindberg's long and international experience in the pharmaceutical industry, experience as a consultant to big companies and knowledge of building value in entrepreneurial companies are considered to be of great importance for value creation in Karessa Pharma.
Ulf Lindberg (born 1952) has more than 15 years’ experience from the pharmaceutical industry. For 7 years he was responsible for sales and marketing roles at the American company Lederle, and also for clinical research. Thereafter, Pharmacia for 8 years as Head of Marketing in Scandinavia, Director Business Area Allergy globally and later member of the executive committee as Head of communication. Later Ulf founded Eductus/Competencia, which had a turnover of approximately SEK 250 million in year 3, and then Sweden's largest commercial education company. After that, Ulf was CEO for Pricer in the USA for 4 years. Today he is CEO at Enhancer and works as advisor to companies and organizations on request of owners, boards and top management.
Michael Brobjer
Michael Brobjer's long and broad experience from head positions, drug development, sales and marketing internationally in the pharmaceutical industry is considered to be of great value for the development of Karessa Pharma.
Michael Brobjer (born 1960) has an MSc in Chemical Engineering. Michael has 30 years of experience from drug development, project management and management positions in marketing, sales and business development at pharmaceutical companies. Most recently he worked at APL, where he has successfully been Director of Marketing & Business Area Life science for 8 years with responsibility for business development. APL develops and manufactures pharmaceuticals to companies worldwide and have a turnover of SEK 1.2 billion. Previously, Michael has also worked at Biovitrum, Pharmacia&Upjohn and KabiPharmacia. His experience as a leader and manager, along with a good understanding of the drug development chain, provides him with a good opportunity to succeed in drug development and commercialization of products in Karessa Pharma.
Comment from Ulf Lindberg
"The market for erectile dysfunction has a turnover of SEK 35 billion in 2012. Of course, there are great opportunities for the products that Karessa develops. The need for more quick-acting and reliable products in this large market is among the users. At the same time, the big pharmaceutical companies are in need for licensing more effective therapies with great commercial potential. Together with CEO and the Board, I look forward to develop Karessa's products and creating value for Karessa's shareholders" says Ulf Lindberg.
Comment from incoming CEO Michael Brobjer
"Ulf Lindberg will be a valuable asset for the company and I look forward to work with him. During my time at APL, I have get to know the patented drug delivery platform, which Karessa has exclusive access to in the area of erectile dysfunction. Erectile dysfunction affects about half of all men over 40 years. The goal is to increase the quality of life for as many of these men as possible" says Michael Brobjer.
About Karessa
Karessa develops pharmaceuticals in the form of thin bioorganic films with the active substances in Viagra respective Levitra. The films are smaller than a postal stamp and is placed on the inside of the chin. Where it dissolves as the drug is delivered directly into the bloodstream via the oral mucosa. By this way the drug is delivered into the body and a quick and reliable onset is achieved.
FOR MORE INFORMATION, PLEASE CONTACT:
Scott Boyer, scott.boyer@klaria.com
Tel: +46 8-446 42 99 / +46 730-71 64 62
About Karessa Pharma Holding AB
Karessa's unique technology allows pharmaceuticals to take a shortcut to the right place in the body. Karessa develops new pharmaceuticals based on proven pharmaceutical substances in order to offer men with impotence problems a fast and more reliable effect. Two pivotal clinical programmes with Karessa's most advanced projects, based on the active substance in Viagra, are expected to be initiated during 2017. Karessa is listed on Nasdaq First North and has Remium as Certified Advisor. For more information, please visit karessa.se
Tags: